32,229 results match your criteria Atopic Dermatitis


Extensive eczema herpeticum in a previously well child.

Int J Emerg Med 2022 May 21;15(1):21. Epub 2022 May 21.

Department of Pediatrics, Salmaniya Medical Complex, Manama, Bahrain.

Background: Eczema herpeticum, also known as Kaposi varicelliform eruption, is a potentially life-threatening disseminated cutaneous viral infection. In the majority of cases, this condition develops as a complication in patients with atopic dermatitis. However, it may arise in a wide spectrum of pre-existing skin conditions, including psoriasis, seborrheic dermatitis, contact dermatitis, cutaneous T cell lymphoma, pemphigus vulgaris, and others. Read More

View Article and Full-Text PDF

Current and Emerging Strategies to Inhibit Type 2 Inflammation in Atopic Dermatitis.

Dermatol Ther (Heidelb) 2022 May 21. Epub 2022 May 21.

Sanofi, 450 Water Street, Cambridge, MA, USA.

Type 2 immunity evolved to combat helminth infections by orchestrating a combined protective response of innate and adaptive immune cells and promotion of parasitic worm destruction or expulsion, wound repair, and barrier function. Aberrant type 2 immune responses are associated with allergic conditions characterized by chronic tissue inflammation, including atopic dermatitis (AD) and asthma. Signature cytokines of type 2 immunity include interleukin (IL)-4, IL-5, IL-9, IL-13, and IL-31, mainly secreted from immune cells, as well as IL-25, IL-33, and thymic stromal lymphopoietin, mainly secreted from tissue cells, particularly epithelial cells. Read More

View Article and Full-Text PDF

New Topical Therapies in Development for Atopic Dermatitis.

Drugs 2022 May 21. Epub 2022 May 21.

Department of Dermatology, Centro Hospitalar do Porto, Porto, Portugal.

Atopic dermatitis (AD) is a common chronic pruritic inflammatory cutaneous disease. AD is characterized by intense pruritus and enormous clinical heterogeneity. Treatment goals are to improve skin lesions and minimize exacerbations and symptom burden. Read More

View Article and Full-Text PDF

The PLAUR signaling promotes chronic pruritus.

FASEB J 2022 Jun;36(6):e22368

Faculty of Science and Health, National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland.

Chronic itch is a complex sensation of the skin frequently associated with skin diseases, such as atopic dermatitis (AD) and psoriasis. Although Serpin E1 is implicated in chronic itch, its receptor and signaling pathways involved in itch are not known. In this study, the clinical relevance of a putative Serpin E1 receptor PLAUR to chronic itch, and the neuro-cutaneous Serpin E1-PLAUR signaling are explored. Read More

View Article and Full-Text PDF

Ambient air pollutants increase the risk of immunoglobulin E-mediated allergic diseases: a systematic review and meta-analysis.

Environ Sci Pollut Res Int 2022 May 20. Epub 2022 May 20.

Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, China.

Immunoglobulin E (IgE)-mediated allergic diseases, including eczema, atopic dermatitis (AD), and allergic rhinitis (AR), have increased prevalence in recent decades. Recent studies have proved that environmental pollution might have correlations with IgE-mediated allergic diseases, but existing research findings were controversial. Thus, we performed a comprehensive meta-analysis from published observational studies to evaluate the risk of long-term and short-term exposure to air pollutants on eczema, AD, and AR in the population (per 10-μg/m increase in PM and PM; per 1-ppb increase in SO, NO, CO, and O). Read More

View Article and Full-Text PDF

The Eczema Area and Severity Index-A Practical Guide.

Dermatitis 2022 May-Jun 01;33(3):187-192

From the Oregon Health & Science University, Portland.

Abstract: Atopic dermatitis is a chronic inflammatory skin condition that affects approximately 18 million people in the United States. Assessing the extent and severity of atopic dermatitis is critical for determining baseline disease burden and treatment effectiveness for both investigators and clinicians. Considerable efforts over the past several decades have been made in developing a highly validated instrument called the Eczema Area and Severity Index (EASI). Read More

View Article and Full-Text PDF

Effectiveness and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps and associated comorbidities: a multicentric prospective study in real life.

Clin Mol Allergy 2022 May 19;20(1). Epub 2022 May 19.

UO Allergologia e Immunologia Clinica, ASST Mantova, Mantova, Italy.

Background: Biologics are currently one of the main treatment options for a number of diseases. The IgG4 monoclonal antibody dupilumab targets the Interleukin-4 receptor alpha chain, thus preventing the biological effects of the cytokines IL-4 and IL-13, that are essential for the Th2 response. Several controlled trials showed that dupilumab is effective and safe in patients with atopic dermatitis (AD), severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), thus resulting in approval by regulatory agencies. Read More

View Article and Full-Text PDF

Baseline Demographics and Severity and Burden of Atopic Dermatitis in Adult Patients Initiating Dupilumab Treatment in a Real-World Registry (PROSE).

Dermatol Ther (Heidelb) 2022 May 20. Epub 2022 May 20.

Regeneron Pharmaceuticals, Inc, 777 Old Saw Mill River Road, Tarrytown, NY, 10591, USA.

Introduction: Dupilumab was initially approved in 2017 as the first biologic therapy for atopic dermatitis (AD). We characterized adults with AD initiating dupilumab in a real-world setting in the USA/Canada.

Methods: PROSE is an ongoing, longitudinal, prospective, observational, multicenter registry of patients with AD initiating dupilumab per country-specific prescribing information. Read More

View Article and Full-Text PDF

Atopic dermatitis mediates the association between an IL4RA variant and food allergy in school-aged children.

J Allergy Clin Immunol Pract 2022 May 16. Epub 2022 May 16.

Harvard Medical School, Boston, MA; Division of Pulmonary and Critical Care, Massachusetts General Hospital, Boston, MA; Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA. Electronic address:

Background: Atopic dermatitis (AD) and food allergy (FA) may share genetic risk factors. It is unknown whether genetic factors directly cause FA or are mediated through AD, as the dual-allergen hypothesis suggests.

Objective: To test the hypothesis that AD mediates the relationship between an interleukin-4 receptor alpha chain gene (IL4RA) variant, the IL4Rα-R576 polymorphism, and FA. Read More

View Article and Full-Text PDF

Dupilumab Associated Head and Neck Dermatitis Resolves Temporarily with Itraconazole therapy, and Rapidly with Transition to Upadacitinib, with Malassezia-Specific IgE Levels Mirroring Clinical Response.

J Am Acad Dermatol 2022 May 16. Epub 2022 May 16.

Department of Dermatology, Liverpool Hospital, Sydney, Australia; Laboratory of Translational Cutaneous Medicine, Ingham Institute, Sydney; University of New South Wales, Sydney, Australia.

View Article and Full-Text PDF

Abrocitinib: A New FDA-Approved Drug for Moderate-to-Severe Atopic Dermatitis.

Ann Pharmacother 2022 May 19:10600280221096713. Epub 2022 May 19.

Department of Dermatology, Center for Dermatology Research, Wake Forest School of Medicine, Winston-Salem, NC, USA.

Objective: The objective of this article is to review abrocitinib, an oral Janus kinase (JAK) 1 inhibitor, for the treatment of patients with moderate-to-severe atopic dermatitis (AD).

Data Sources: A literature search of MEDLINE (PubMed) was performed for articles from inception through end-March 2022 using the following search terms: atopic dermatitis, abrocitinib, PF-04965842, methotrexate, cyclosporine, dupilumab, ruxolitinib, and JAK-STAT pathway.

Study Selection And Data Extraction: English articles relating to pharmacology, pharmacokinetics, efficacy, and safety of abrocitinib, and other conventional systemic medications for AD, were included. Read More

View Article and Full-Text PDF

Epidemiological variations in global burden of atopic dermatitis, an analysis of trends from 1990 to 2019.

Allergy 2022 May 19. Epub 2022 May 19.

Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China, 200443.

View Article and Full-Text PDF

Dermatological uses of rice products: trend or true?

J Cosmet Dermatol 2022 May 19. Epub 2022 May 19.

Baylor College of Medicine.

Rice has been used for cosmetic purposes for centuries and its benefits have been translated into modern-day skin care products. Individual components of rice have been identified including phenolic compounds, betaine, squalene, tricin, and rice bran. These rice-derived ingredients have been found to be antiaging, anti-inflammatory, whitening, photoprotective, and moisturizing. Read More

View Article and Full-Text PDF

Speed of onset of a new chewable formulation of oclacitinib maleate (Apoquel®) in a canine model of IL-31-induced pruritus.

J Vet Pharmacol Ther 2022 May 19. Epub 2022 May 19.

Veterinary Medicine Research & Development, Zoetis, Inc., Kalamazoo, Michigan, USA.

Oclacitinib maleate (Apoquel®, Zoetis Inc.) is commonly used around the world for the control/treatment of pruritus associated with allergic dermatitis and the control/treatment of atopic dermatitis in dogs at least 12 months of age. A new flavored chewable formulation of oclacitinib has been developed where more than 90% of doses offered to dogs were freely accepted when tested in clinical trials. Read More

View Article and Full-Text PDF

Exploration of the Potential Mechanism of the Common Differentially Expressed Genes in Psoriasis and Atopic Dermatitis.

Biomed Res Int 2022 9;2022:1177299. Epub 2022 May 9.

Department of Dermatopathology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China.

Backgrounds: Psoriasis and atopic dermatitis are two common chronic inflammatory skin diseases that enormously deteriorate the psycho-physical and socio-economic condition of the patients. Although differential immune responses have been found to operate in the pathomechanisms of atopic dermatitis and psoriasis, the epidermal keratinocytes are the major targets in both diseases, and sometimes, they show similar clinical presentations. The skin barrier, itching, and inflammation are current and future treatment targets for both of them, but the relevant shared mechanisms of the two diseases are far from understood. Read More

View Article and Full-Text PDF

Desire for Alternative Treatment Options in Patients with Atopic Dermatitis in Japan: Results of a Web-Based Cross-Sectional Study (AD-JOIN Study).

Dermatol Ther (Heidelb) 2022 May 18. Epub 2022 May 18.

Medical Department, AbbVie GK, 3-1-21 Shibaura, Minato-ku, Tokyo, 108-0023, Japan.

Introduction: Treatment satisfaction in patients with atopic dermatitis (AD) has been investigated in several studies, but the desire for alternative treatment options is unclear and has not been previously evaluated. We conducted a cross-sectional, web-based survey aimed at evaluating the desire for alternative treatment options in adults with AD from a patient registry in Japan.

Methods: Main eligibility criteria were adults aged ≥ 18 years with AD who were receiving treatment with topical corticosteroids (TCS) and not systemic therapy. Read More

View Article and Full-Text PDF

Molecular and cellular mechanisms of itch and pain in atopic dermatitis and implications for novel therapeutics.

Clin Transl Immunology 2022 9;11(5):e1390. Epub 2022 May 9.

Department of Dermatology and Venereology Hamad Medical Corporation Doha Qatar.

Atopic dermatitis is a chronic inflammatory skin disease. Patients with atopic dermatitis experience inflammatory lesions associated with intense itch and pain, which lead to sleep disturbance and poor mental health and quality of life. We review the molecular mechanisms underlying itch and pain symptoms in atopic dermatitis and discuss the current clinical development of treatments for moderate-to-severe atopic dermatitis. Read More

View Article and Full-Text PDF

Topical delivery of pluronic F127/TPGS mixed micelles-based hydrogel loaded with glycyrrhizic acid for atopic dermatitis treatment.

Drug Dev Ind Pharm 2022 May 17:1-18. Epub 2022 May 17.

Department of Pharmacy, Jiangxi Provincial People's Hospital, Nanchang 330006, China.

Objective: The purpose of this study was to develop pluronic F127/D-a-tocopheryl polyethylene glycol 1000 succinate mixed micelles-based hydrogel (MMs-gel) for topical delivery of GL to improve its skin permeability and atopic dermatitis (AD) treatment.

Significance: GL loaded MMs-gel (GL-MMs-gel) could be potentially used as a promising nanocarrier for the treatment of AD.

Methods: GL-MMs were prepared by thin film hydration method and then loaded into carbopol gel. Read More

View Article and Full-Text PDF

Long-term Remission of Atopic Dermatitis after Discontinuation of Dupilumab.

Acta Derm Venereol 2022 May 17. Epub 2022 May 17.

Department of Dermatology, Hyogo College of Medicine, 1-1, Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan.

View Article and Full-Text PDF

Genome-wide integration of genetic and genomic studies of atopic dermatitis: Insights into genetic architecture and pathogenesis.

J Invest Dermatol 2022 May 13. Epub 2022 May 13.

Institute of Systems and Physical Biology, Shenzhen Bay Laboratory, Shenzhen 518107, China. Electronic address:

Atopic dermatitis (AD) is a common heterogeneous, chronic, itching, and inflammatory skin disease. Genetic studies have identified multiple AD susceptibility genes. However, the genetic architecture of AD has not been elucidated. Read More

View Article and Full-Text PDF

Epigenetic and transcriptional dysregulation in CD4+ T cells in patients with atopic dermatitis.

PLoS Genet 2022 May 16;18(5):e1009973. Epub 2022 May 16.

Division of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States of America.

Atopic dermatitis (AD) is one of the most common skin disorders among children. Disease etiology involves genetic and environmental factors, with 29 independent AD risk loci enriched for risk allele-dependent gene expression in the skin and CD4+ T cell compartments. We investigated the potential epigenetic mechanisms responsible for the genetic susceptibility of CD4+ T cells. Read More

View Article and Full-Text PDF

Evaluation of a hydrolysed salmon and pea hypoallergenic diet application in dogs and cats with cutaneous adverse food reaction.

Pol J Vet Sci 2022 Mar;25(1):67-73

Independent Unit of Spectroscopy and Chemical Imaging, Faculty of Biomedicine, Medical University of Lublin, ul. W. Chodzki 4a, 20-093 Lublin, Poland.

Cutaneous adverse food reaction (CAFR) is a common disease, affecting about 1-2% of dogs and cats. Diagnosis of the CAFR is made through elimination diet coupled with diet challenge, as methods like skin tests, patch tests, basophil degranulation tests and assessment of IgG and IgE serum levels are not sensitive enough. A partially hydrolysed salmon and pea hypoallergenic diet was evaluated in the diagnosis and treatment of CAFR in dogs and cats. Read More

View Article and Full-Text PDF

Atopic dermatitis: pathomechanisms and lessons learned from novel systemic therapeutic options.

J Eur Acad Dermatol Venereol 2022 May 16. Epub 2022 May 16.

Department of Dermatology and Allergy, University Hospital, Ludwig Maximillian University, Munich, Germany.

Atopic dermatitis (AD) is a chronic, heterogenous, inflammatory skin disorder associated with a high skin-related health burden, typically starting in childhood and often persisting into adulthood. AD is characterized by a wide range of clinical phenotypes, reflecting multiple underlying pathophysiological mechanisms and interactions between genetics, immune system dysregulation, and environmental factors. In this review, we describe the diverse cellular and molecular mechanisms involved in AD, including the critical role of T cell-driven inflammation, primarily via T helper (Th) 2- and Th17-derived cytokines, many of which are mediated by the Janus kinase (JAK) signaling pathway. Read More

View Article and Full-Text PDF

Severe atopic dermatitis in a 21-month-old boy successfully treated with dupilumab.

Pediatr Dermatol 2022 May 16. Epub 2022 May 16.

Department of General Paediatrics, Queensland Children's Hospital, Brisbane, Queensland, Australia.

While dupilumab has emerged as a novel targeted systemic treatment for severe AD, efficacy and safety-based data in young children are limited. We discuss the case of a 21-month-old child with severe recalcitrant atopic dermatitis successfully treated with dupilumab. Read More

View Article and Full-Text PDF

Atopic dermatitis leading to failure to thrive: A case report.

Pediatr Dermatol 2022 May 16. Epub 2022 May 16.

Duke Dermatology Department, Durham, North Carolina, USA.

We present an infant with severe atopic dermatitis, protein loss, and subsequent failure to thrive. With proper management, the patient's laboratory findings normalized, and he gained weight appropriately. In this report, we highlight the impact that severe atopic dermatitis may have growth and development and review the genetic conditions that can result in a similar clinical presentation. Read More

View Article and Full-Text PDF